Literature DB >> 18452063

Molecular genetic characterization reveals new subsets of mantle cell lymphoma.

Emma Flordal Thelander1, Richard Rosenquist.   

Abstract

Mantle cell lymphoma (MCL) is an aggressive B-cell malignancy, which is believed to originate from naive B-cells in the mantle zone of lymph nodes. Recently, a more diverse cellular origin has been implicated in MCL, since the disease was shown to consist of two subsets based on immunoglobulin heavy-chain variable (IGHV) gene analysis; a major subset with unmutated IGHV genes and a smaller subset (approximately 20 to 30%) displaying mutated IGHV genes. Presence of somatic hypermutation in the 'mutated' subset suggests either exposure to a germinal centre (GC) environment or that somatic hypermutation has been acquired in a non-GC context. Furthermore, a preferential IGHV gene utilization has been revealed in MCL, where IGHV3-21 and IGHV4-34 are the most predominant. MCLs with an IGHV3-21 usage almost exclusively share the same light chain (IGLV3-19) use and this subset is also related to a better prognosis. MCL cases utilising the IGHV3-21 gene display less chromosomal alterations than MCLs using other IGHV genes and in addition, gains in 15q and losses in 9p were not observed in any of these cases. These latter findings are in favour of the hypothesis that IGHV3-21(+) tumours may represent a distinct MCL subentity and that there is a possible role for antigens in MCL development. In this review, we will summarise these recent studies of IG gene rearrangements in MCL as well as molecular cytogenetic characteristics of this malignancy.

Entities:  

Mesh:

Year:  2008        PMID: 18452063     DOI: 10.1080/10428190801947559

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  14 in total

Review 1.  Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities.

Authors:  Nicholas Chiorazzi; Manlio Ferrarini
Journal:  Blood       Date:  2010-12-09       Impact factor: 22.113

Review 2.  Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era.

Authors:  Patricia Pérez-Galán; Martin Dreyling; Adrian Wiestner
Journal:  Blood       Date:  2010-10-12       Impact factor: 22.113

Review 3.  Targeting B-cell receptor signaling in leukemia and lymphoma: how and why?

Authors:  John C Allen; Fatima Talab; Joseph R Slupsky
Journal:  Int J Hematol Oncol       Date:  2016-05-26

4.  TP53 mutation is not an independent prognostic factor in patients with mantle cell lymphoma at advanced stage.

Authors:  Hua-Jie Dong; Li-Tao Zhou; Cheng Fang; Lei Fan; Dan-Xia Zhu; Yin-Hua Wang; Jian-Yong Li; Wei Xu
Journal:  Med Oncol       Date:  2011-11-06       Impact factor: 3.064

Review 5.  Mantle cell lymphoma: a clinically heterogeneous disease in need of tailored approaches.

Authors:  Bijal D Shah; Peter Martin; Eduardo M Sotomayor
Journal:  Cancer Control       Date:  2012-07       Impact factor: 3.302

6.  An uncommon case of de novo CD10+ CD5- mantle cell lymphoma mimics follicle center B cell lymphoma.

Authors:  Mauricio Zapata; Steven D Budnick; Rodolfo Bordoni; Shiyong Li
Journal:  Int J Clin Exp Pathol       Date:  2010-03-20

7.  Molecular Cytogenetic Characterization Identified the Murine B-Cell Lymphoma Cell Line A-20 as a Model for Sporadic Burkitt's Lymphoma.

Authors:  Karolina Guja; Thomas Liehr; Martina Rincic; Nadezda Kosyakova; Shaymaa S Hussein Azawi
Journal:  J Histochem Cytochem       Date:  2017-09-13       Impact factor: 2.479

8.  Medical history, lifestyle, family history, and occupational risk factors for mantle cell lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project.

Authors:  Karin E Smedby; Joshua N Sampson; Jennifer J Turner; Susan L Slager; Marc Maynadié; Eve Roman; Thomas M Habermann; Christopher R Flowers; Sonja I Berndt; Paige M Bracci; Henrik Hjalgrim; Dennis D Weisenburger; Lindsay M Morton
Journal:  J Natl Cancer Inst Monogr       Date:  2014-08

Review 9.  B-cell receptor signaling as a driver of lymphoma development and evolution.

Authors:  Carsten U Niemann; Adrian Wiestner
Journal:  Semin Cancer Biol       Date:  2013-09-20       Impact factor: 15.707

10.  CD10-positive mantle cell lymphoma: clinicopathologic and prognostic study of 30 cases.

Authors:  Jie Xu; L Jeffrey Medeiros; Annapurna Saksena; Michael Wang; Jiehao Zhou; Jingyi Li; C Cameron Yin; Guilin Tang; Lifu Wang; Pei Lin; Shaoying Li
Journal:  Oncotarget       Date:  2017-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.